CCND2 and Miyoshi myopathy: In conclusion, we showed that the implementation of dimensionality-reduction techniques for the analysis of CNAs genomic profile of a large cohort of newly diagnosed MM patients allowed to define a segment of patients carrying a homogeneous genomic and transcriptomic profile, characterized by the over-expression of CCND2 and whose biomarker is the co-occurrence of gain 1q and loss 13q.